This review is limited by the differences in the characteristics of the included studies, including study populations and outcome measures. However, it found little research to support the use of nasal saline for acute URTIs. Included studies showed limited benefit for symptoms relief with nasal saline irrigation in adults. Nasal saline is safe and may reduce time off work but may cause minor adverse effects such as dry nose or irritation in less than half of users.
Future studies are needed to establish the use of nasal saline irrigation as a way of reducing acute URTI symptoms safely while keeping people at work and reducing antibiotic use.
B A C K G R O U N D Description of the condition
Acute upper respiratory tract infections (URTIs) involve the upper airways (the nose, sinuses, larynx and pharynx). Examples include the common cold, influenza, rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis and otitis media. Acute infections are those with symptoms lasting up to 28 days (Meltzer 2006) . Acute URTIs are common and symptoms include fever, sore throat and nasal congestion, which can be painful and debilitating, and are a major cause of employee absence in the workforce. The economic impact of the common cold alone on workplace absenteeism is estimated to be billions of dollars (Bramley 2002) .
Description of the intervention
Usual treatments for URTIs include antipyretic and analgesic drugs, mucolytics, expectorants and decongestants (Simasek 2007) . While acute URTIs are mainly caused by viruses, antibiotics are often prescribed (Nash 2002) . This may lead to increased antibiotic resistance and adverse outcomes, as well as being unnecessary for the patient.
How the intervention might work
Saline irrigation of the nose, which is a popular treatment for sinonasal conditions, is believed to alleviate URTI symptoms by clearing excess mucus, reducing congestion and improving breathing (Tomooka 2000) . It is known to improve mucociliary clearance by increasing the ciliary beat frequency (Talbot 1997). As well as relieving sinonasal symptoms, saline irrigation may remove infectious material from the sinuses, and reduce cough associated with postnasal drip (Kaliner 1998). Nasal saline irrigation is sometimes used as an effective treatment for chronic sinusitis (Rabago 2002) and allergic rhinitis (Garavello 2003) . It has been used as monotherapy or as an adjunct to other treatments, such as oral antihistamines. It is available commercially in various concentrations and formulations of salts, and is usually delivered by atomised spray or larger volumes for lavage.
Why it is important to do this review
If effective, nasal saline treatment could potentially reduce the burden of disease and workplace absenteeism resulting from such infections. It may also reduce the over-prescription of antibiotics for acute URTIs. One review of the existing literature (Papsin 2003) found that most trials of nasal saline in acute URTIs were very small, with some being uncontrolled experiments. Though not a systematic review, Papsin 2003 evaluated the evidence as "fair". A Cochrane Review (Harvey 2007) assessed nasal saline irrigation as a treatment for chronic rhinosinusitis and found it may be useful in providing symptomatic relief, without significant side effects. This systematic review evaluates the efficacy of saline irrigation in the treatment of acute URTIs, to determine whether saline nasal irrigation improves respiratory symptoms of acute URTIs.
O B J E C T I V E S
The primary objective was to assess the efficacy of saline nasal irrigation for symptom reduction in patients with acute URTIs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing topical nasal saline treatment (liquid, drops or spray) with at least one other intervention. We also included studies trialling another therapy, where saline irrigation was used as a control treatment. We excluded non-RCTs or non-comparative studies and trials involving patients with chronic URTIs or allergic rhinosinusitis. Treatment studies for acute URTIs were included; prevention studies for acute URTIs were excluded.
Types of participants
We included adults and children diagnosed with acute URTIs featuring nasal and/or sinus symptoms for less than 12 weeks. (Types of acute URTIs include rhinosinusitis, pharyngitis, otitis media, tonsillitis, common cold and influenza). We excluded studies involving patients with allergic respiratory symptoms, chronic respiratory infections or chronic diseases with respiratory features, such as cystic fibrosis, or recovering from sinus surgery.
Types of interventions
We compared the following interventions. 1. Nasal lavage, irrigation, or similar topical nasal liquid saline treatment, compared with a placebo.
2. Nasal lavage, irrigation, or similar topical nasal liquid saline treatment, compared with other standard treatment.
3. Nasal saline plus standard treatment compared with standard treatment alone.
Comparative treatments were different topical medications or other treatment methods. We included studies using atomised or nebulised saline. We also included trials of all types of topical saline treatments, including isotonic and hypertonic solutions, as well as commercially available saline preparations.
Types of outcome measures
Primary outcomes 1 . Improvement of acute URTI-related symptoms (for example, nasal discharge, congestion, sneezing, headache) over periods up to 28 days.
2. Duration and severity of symptoms. 
Data collection and analysis

Selection of studies
One review author (JK) selected the studies. Two review authors (DK, GS) checked the results.
Data extraction and management
Two review authors (DK, GS) independently extracted and summarised details of the studies using a data extraction sheet. Data extracted included year and country of study, study population, methodological quality, type of saline solution used, any adverse events and outcomes. We contacted trial authors for missing information where possible. However, none replied with data. Data were managed and analysed using Review Manager software, version 5 (RevMan 2008).
Assessment of risk of bias in included studies
We assessed trials for risk of bias and appropriateness for inclusion. We processed data from included trials as described in the Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 (Higgins 2008). We undertook risk of bias assessment by evaluating the following components for each included study.
1. The method of generation of the randomisation sequenceif it delivered a known chance allocation to each given group, but individual allocation could not be anticipated.
2. The method of allocation concealment -considered 'adequate' when the assignment could not be foreseen.
3. Who was masked or unmasked to the intervention (participants, clinicians, outcome assessors).
4. Participants lost to follow up in each arm of the study (split into post-randomisation exclusions and later losses if possible), and whether participants were analysed in the groups to which they were originally randomised (intention-to-treat). In addition, we collated aspects related to follow up, participants lost to follow up, protocol violations and sample size determinations. We recorded the information in 'Risk of bias' tables and gave a description of the quality of each study, based on a summary of these components.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
We assessed three studies (Adam 1998; Bollag 1984; Slapak 2008) as meeting most criteria for low risk of bias and we selected these for inclusion in the review. Two studies (Inanli 2002; Passali 2005) were assessed as having a higher risk of bias. Problems with these two studies included inadequate description of the method of randomisation (or doubt as to randomisation used), unblinded trials and inadequate data analysis. Additionally, Inanli 2002 was assessed as not fully meeting the review criteria as it measured one biological parameter (mucociliary clearance) but not clinical symptoms of acute URTI. We excluded these two studies.
Results of the search
The databases we searched yielded the following results: 146 articles in MEDLINE, 68 articles in EMBASE, 49 articles in CEN-TRAL, 22 results in CINAHL and no articles in AMED or LILACS. Of the total 285 trials retrieved, 280 were excluded based on a review of titles and abstracts. Of the five remaining trials, we assessed three as meeting the inclusion criteria, and excluded two as not meeting the minimum quality criteria. A QUORUM (quality of reporting of meta-analyses) flowchart of study selection is attached (Figure 1) . After screening the full text of the selected trials, three met the inclusion criteria. The included trials were published in 1984, 1998 and 2008. All were published in English. 
Included studies
Adam 1998 met the inclusion criteria as it randomised adults in the USA with clinically diagnosed acute rhinosinusitis or common cold to one of three groups: hypertonic nasal saline irrigation, normal saline irrigation or no treatment (control). Bollag 1984 met the inclusion criteria as children in the USA with clinically diagnosed acute URTIs were randomised to treatment with normal saline drops, phenylephrine drops or no treatment. Slapak 2008 met the inclusion criteria as children in the Czech republic with clinically diagnosed common cold or influenza were randomised to receive standard treatment with or without adjunct nasal irrigation with isotonic saline. The study divided the patients receiving nasal saline treatment into three subgroups using different delivery strengths: fine spray, medium jet flow and fine spray eye and nose wash. Each subgroup used the same solution of commercial isotonic seawater. Results were reported for each subgroup and for the saline group as a whole; this review considers the results for the saline group as a whole. We contacted the authors of each included trial to provide missing raw data for the studies, but none were provided.
Excluded studies
We excluded two trials (Inanli 2002; Passali 2005) after evaluation. The main reasons for exclusion were lack of description of randomisation, unblinded studies and inadequate data analysis. Mucociliary clearance, the only outcome measure used by Inanli 2002, was further assessed to be an unsuitable measure for acute URTI symptoms. Passali 2005 was excluded due to doubt as to proper randomisation of the study. For details, see 'Characteristics of excluded studies' table.
Risk of bias in included studies
None of the included trials used computer generated randomisation for allocating participants to study groups. Two trials (Adam 1998; Bollag 1984) used random number tables. The remaining trials stated allocation was random but did not describe the method.
Allocation
None of the included trials described the method of allocation concealment used.
Blinding
Each included trial was only partially blinded (patients, clinicians or outcome assessors; sometimes two, but not all three), suggesting some risk of biased results. In particular, the design of Slapak 2008 made patient blinding largely impossible as each participant either used the saline spray or did not. The outcome assessors were blinded only to the type of saline spray delivery used, and not blinded as to whether or not participants were using the saline treatment. Participants and clinicians were blinded in Adam 1998, but blinding of outcome assessors was not discussed. Conversely, the outcome assessors in Bollag 1984 were blinded to patient treatment group, but blinding of participants (and parents) was not discussed.
Incomplete outcome data
Adam 1998 omitted any discussion of participants lost to follow up, although intention-to-treat analysis was performed. The other included trials (Bollag 1984; Slapak 2008) adequately discussed drop-out and losses to follow up.
Effects of interventions
The clinical measures used in the included studies were so heterogenous as to only allow minimal pooling of data. Other than nasal symptom score (assessed both by Adam 1998 and Bollag 1984) the results from each study must be analysed individually. There was no significant difference in clinical symptom scores between control and intervention groups in the included trials. The only notable difference between groups was the respiratory symptom score on day one (Bollag 1984), where a slightly higher average score was found in the phenylephrine group compared to the normal saline group. The mean difference was -0.65 (95% confidence interval (CI) -1.11 to -0.19), indicating a small difference. Overall, baseline clinical features of the groups in each study were comparable, with no other significant differences.
Primary outcomes Nasal symptom score
Comparison of nasal symptom score at day three between saline irrigation groups and those receiving either another treatment or a placebo revealed no statistically significant differences between any of the groups. Notably, the nasal symptom score at day three, combining two included studies (Adam 1998; Bollag 1984), showed no difference between the saline nasal irrigation group and the observation only group, with a standard mean difference of -0.07 (95% CI -0.45 to 0.31). Adam 1998 used a four-point symptom scale, from 0 (no symptoms) to 3 (severe symptoms); Bollag 1984 used a similar scale, with 1 representing severe symptoms and 4 indicating no symptoms.
Nasal secretion score
Participants studied by Slapak 2008 were assessed at the first and second visits for type of nasal secretions, and the qualitative assessment (absent, serous, seropurulent or purulent) translated to a numerical score for grouping of results. The mean difference for comparison of the saline wash and control groups at second visit was -0.34 (95% CI -0.49 to -0.19), indicating a small improvement with nasal saline irrigation. Time to symptom resolution in one study (Adam 1998) did not differ significantly between groups.
Nasal patency
Slapak 2008 evaluated the degree of difficulty of nasal breathing as a "breathing score" for each patient at the first and second visits. The mean difference for the saline wash group compared with the control group at the second visit was -0.33 (95% CI -0.47 to -0.19). Like the nasal secretion scores, this may suggest improvement in the saline wash group.
Respiratory symptom score
Only one included study (Bollag 1984) provided respiratory symptom scores for each group of patients. At day three, there was no significant difference in respiratory symptom score between any of the compared treatment or control groups. The mean difference for comparison of saline nasal drops and observation was -0.25 (95% CI -0.73 to 0.28).
Activity symptom score
This is a score reflecting the child's degree of wellness in terms of behaviours such as feeding and sleeping. Analysis of the data for activity symptom score at day three (Bollag 1984) showed no statistically significant difference between any of the compared treatment or control groups. However there was a trend towards improvement with nasal saline irrigation over observation only, with a mean difference of -0.29 (95% CI -0.68 to 0.10).
Secondary outcomes Day of well-being
One study (Adam 1998) included data on the 'day of well-being' for patients in each group, indicating on which day participants felt 'back to normal' (see Table 1 ). The mean day of well-being for the group treated with hypertonic nasal saline irrigation was 8.30 (95% CI 6.90 to 9.70). The normal saline group had a mean day of well-being of 8.30 (95% CI 6.82 to 9.78). Comparatively, the control group that received no treatment had a mean day of wellbeing of 8.00 (95% CI 6.70 to 9.30). There was no statistically significant difference in mean day of well-being between any of the groups.
Overall health status
Slapak 2008 included health status scores, indicating the degree of symptomatic improvement based on physician examination (see Table 2 ). Scores were given on a scale of 1 to 4, with a health status score of 1 indicating no symptoms, and a score of four representing severe symptoms. The mean health status score at the follow-up examination was 2.06 (95% CI 1.93 to 2.19) for the control group, compared with 1.72 (95% CI 1.66 to 1.78) for the saline wash group. This suggests a statistically significant benefit of nasal saline wash. Time to symptom resolution in one study (Adam 1998) did not differ significantly between groups.
Antibiotic use
Slapak 2008 found a trend to reduced antibiotic use in the nasal saline group, though this did not reach statistical significance (see Table 3 ).
Time off work
Significantly fewer participants in the nasal saline group required time off work compared to the observation group in one study (Slapak 2008).
Adverse effects
All included studies reported adverse effects from treatment with nasal saline, or difficulty with patient toleration of treatment. These are summarised in Table 4 . The study using infant patients (Bollag 1984) reported six out of 15 participants (40.0%) did not tolerate treatment with saline nasal drops, while seven out of 16 (43.7%) did not tolerate treatment with phenylephrine drops. While the group numbers are small, the similar proportions suggest the infants may not have tolerated the delivery of nasal drops, rather than the saline itself. The study using adult patients (Adam 1998) found no participants reporting intolerance of the treatment. However, in the group using hypertonic saline irrigation, seven out of 33 participants (21.2%) complained of dry nose, and 11 out of 33 (33.3%) reported pain or irritation. Among the group treated with normal saline irrigation, 11 out of 36 (30.5%) complained of dry nose, and four out of 31 (12.9%) reported pain or irritation from the treatment. The third study, using children (Slapak 2008), found an overall rate of adverse events of 8.7%, most of which were reported by participants in the medium jet group and associated with the higher flow rate. The trial authors did not specify further the type of complaints but mention that three patients experienced nosebleeds. As none of the papers discuss patient withdrawal in detail, it is possible that some may have left the studies for reasons related to adverse effects or discomfort from treatment.
D I S C U S S I O N
Summary of main results
The included randomised controlled trials (RCTs) of saline nasal irrigation provide limited evidence that treatment is effective for symptoms of acute upper respiratory tract infections (URTIs). Measured symptom scores were statistically similar between treatment and control groups, and the length of time to resolution of symptoms was not clinically significant. There was a trend toward reduced antibiotic use in one study with saline nasal irrigation and this study also demonstrated a statistically significant reduction in time off work with nasal saline irrigation compared to control (Slapak 2008) . No serious adverse effects occurred in the trials reviewed, although three children in one study (Slapak 2008) experienced nose bleeds. Minor adverse events were not uncommon and 40% to 44% of babies were shown to have difficulty with nasal drops. Discomfort in one study (Slapak 2008) was associated with higher application pressures rather than the nasal saline solution itself.
Overall completeness and applicability of evidence
This review focused on RCTs of saline nasal irrigation for the symptomatic treatment of acute URTIs. The nature of saline nasal irrigation makes double-blinding difficult and an appropriate placebo difficult to find. There were a limited number of RCTs available and all of these studies were small in size. Of the three included trials, due to the differences in clinical measures used, only one outcome incorporated pooled data. Each trial reviewed used different strengths of saline solution, again limiting the possibilities for data comparison. In particular, Slapak 2008 used a commercial isotonic seawater product containing zinc and other elements that may be a factor in the effects of the product. Only one of the included papers (Slapak 2008) examined the effect of saline irrigation on other symptoms, such as anosmia (loss of the sense of smell) and cough associated with acute URTIs. This is a potential clinical application of the treatment but no other papers addressing the topic were located. The clinical outcomes measured by each study were largely subjective, focusing on patient-reported symptoms, which increases risk of bias in the results. Furthermore, Bollag 1984 relied on interpretation and reporting of infant patients' symptoms by parents, compounding this effect. This must be considered as a limitation of the studies and outcome measures. 
A U T H O R S ' C O N C L U S I O N S Implications for practice
Limited data from three RCTs suggest that saline nasal irrigation may have some benefit in adults with acute URTIs. While some participants experienced minor discomfort, no serious side effects were identified. Treatment with nasal saline irrigation was associated with less time off work and there is a trend towards less antibiotic use.
Nasal irrigation with saline is a safe treatment that may be mildly beneficial to some patients, though the existing evidence is too limited to recommend it as a standard intervention.
Implications for research
Further RCTs are warranted to establish the place of nasal saline irrigation in acute URTIs and should include clinical relevant respiratory symptoms as outcome measures, including cough. Given the range of different available topical saline treatments, future studies could include comparisons of liquid saline to sprays in the treatment of URTIs.
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A D D I T I O N A L T A B L E S
